Microtubule Anchor Protein Identified

Microtubules help to regulate cell structure throughout our bodies. Using cryo-electron microscopy, light has been shed on how a certain protein keeps microtubules stable, and regulates microtubule-based transport within cells.

The new insights could help to develop medical treatment for diseases such as dementia and heart failure.

Cells in our bodies take on specialized shapes in order to function as part of organs and tissue. For example, nerve cells keep the brain and body closely linked by making a communications network between cell projections. Heart cells form lines of cylinders for effective muscle contraction. To create these shapes, a framework of complex proteins make the cell “skeletons”. The widest of these are known as microtubules, and their placement is regulated by microtubule-associated proteins.

Tau and MAP4 (both part of the Tau family) are “classic” microtubule-associated proteins. Tau is found in nerve cells, while MAP4 is expressed widely throughout our bodies such as the heart or skeletal muscle. Excessive expression of these classic microtubule-associated proteins has been linked to Alzheimer’s disease and heart failure. It can block the movement of motor protein kinesin, which uses microtubules as “rails” to transport various substances within cells.

The research team reconstructed the complex structure of microtubules, MAP4 and motor protein kinesin under laboratory conditions, and used cryo-electron microscopy to visualize the detailed three-dimensional structure.

Results showed that MAP4 attaches to the long axes of microtubules and stabilizes them.

The bonds between MAP4 and microtubules are located at two types of sites: for strong and weak interactions. At the weak sites, kinesin competes with MAP4 to bind with microtubules. If there is sufficient kinesin, it can displace the MAP4 at the weak sites and bind with the microtubules.

This leads to both MAP4 (at the strong anchor sites) and kinesin (at the weak sites) binding with microtubules at the same time. The team found that, as well as binding directly with microtubules, MAP4 also folds and accumulates above the microtubules. The MAP4 in this area interacts with and secures kinesin, blocking the movement of kinesin above the microtubules. This shows how MAP4 stabilizes microtubules, and how it also blocks the transport functions of kinesin.

These findings could help to create a new treatment strategy for cardiac hypertrophy and heart failure caused by overexpression of MAP4. It is also highly possible that Tau, which has an amino-acid sequence very similar to MAP4, could present the same structure. In this case, this study would also shed light on neurodegenerative diseases such as dementia.

Professor Nitta comments: “By revealing the micromorphology of the MAP4 and microtubule complex in cells, we hope this research will provide insights on a cellular level that can help us to combat diseases caused by cell change such as heart failure and dementia.”

This article has been republished from materials provided by Kobe University. Note: material may have been edited for length and content. For further information, please contact the cited source.

RELATED ARTICLES

UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.